Hype around a new medical device that can measure a patient’s blood pressure and exhale has been growing fast, with the product set to be introduced by the end of this year at a medical device summit in Tokyo.
The device will be called a Hype and Hyoid Device, and it will be sold under the name Fireman Breathing, according to a company press release.
The product has been developed by a team at Japanese startup Medivac, a division of the pharmaceutical giant AstraZeneca.
The company, which is also the first to successfully make a lung cancer treatment, has announced it is looking to raise $500 million in a crowdfunding campaign.
The Hype And Hyoid device, which will be released in 2020, will measure the blood pressure of the patient and will also record the amount of oxygen that the patient is exhaling.
A device like this is incredibly helpful to people who have lung cancer because it can provide accurate and consistent blood pressure measurements, which can then be used to improve the patients care, the release states.
It will also be able to monitor patients vital signs such as heart rate, blood pressure, breathing and oxygen levels.
Medivacs CEO Hiroshi Nakamura, who is also a professor at Tokyo’s Kyushu University, told the Tokyo Metropolitan Assembly on Tuesday that MedivAC’s device will also have a “real life” use in the real world.
MedIVAC’s product, which would cost roughly $200,000, will allow doctors to accurately measure the heart rate of a patient.
It would also allow doctors who are not doctors to monitor blood pressure without needing a doctor’s license.
“When a doctor is not able to provide a doctor with accurate measurements, patients may be at risk of developing heart disease,” Nakamura said.
Medievac is also working on a device called a Heart Rate Monitor that uses sensors to track the pulse of a person’s heart.
The Heart Rate monitor is also expected to become available for $100,000 by 2020.
“I think the device will become a very important part of the healthcare system,” Nakimura said.
The release does not say how many people will be able access the device.
Medivation, which develops devices for the pharmaceutical industry, is also planning to unveil a new device that will allow users to “feel” a device they have purchased.
Mediva, which specializes in detecting cancer cells in the body, is currently developing a device that could track a person using electroencephalogram.
Mediapro is also developing a sensor that will let a patient “feel a device,” but this device will only be available for a limited time.
Mediacorp, a unit of the U.S. biotech company Amgen, announced in February that it has also developed a device with a heart rate monitor that is similar to Medivaco’s device.
The Medivaca device will cost $600,000.